Скачать или смотреть Biovie’s Groundbreaking Drug for Long COVID & Parkinson’s | Bloomberg TV | New to The Street Ep. 659

Kush Saxena – Global Fintech Veteran | Former CEO, GetNet, Former SVP MasterCard

Investors and healthcare innovators—don’t miss this exclusive update from Biovie Inc., a clinical-stage biopharma company developing revolutionary treatments for neurological and neurodegenerative disorders.

In New to The Street Ep. 655, host Jane King interviews CEO Khang Do and Advisory Board member Kush Saxena about Biovie’s promising drug candidate, Benzisterum, now in clinical trials for long COVID and Parkinson’s disease. With no current approved therapy for long COVID, Biovie’s approach aims to be the first of its kind. Their Parkinson’s research could lead to the first disease-modifying therapy in over 50 years, going beyond symptom relief to potentially slow neurodegeneration.

Kush Saxena, former Mastercard executive and co-founder of Function Ventures, shares why he joined Biovie’s elite advisory board and how the company’s bold mission aligns with breakthrough biotech innovation.

🧠 Topics covered:

Long COVID’s ongoing impact: 17M+ Americans affected

Benzisterum’s neuroprotective promise for Parkinson’s

Advisory board insights, including Neuralink co-founders and scientific leaders

Storytelling and capital market strategy in biotech

🔔 Subscribe to stay updated on the results of these game-changing clinical trials.

#Biovie #newtothestreet